Evidence map›Paper›PMID 38570764›Full record

ArticleBMC health services research2024

Cost-effectiveness of intraoperative radiation therapy versus intensity-modulated radiation therapy for the treatment of early breast cancer: a disinvestment analysis.

Carlos Muñoz-Montecinos, Catalina González-Browne, Felipe Maza, Diego Carreño-Leiton, Pablo González, Badir Chahuan, Camila Quirland

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Carlos Muñoz-Montecinos *Health Technology Assessment Unit, Arturo Lopez Perez Foundation, Santiago, RM, Chile.
Catalina González-Browne *Health Technology Assessment Unit, Arturo Lopez Perez Foundation, Santiago, RM, Chile. catalina.gonzalez@falp.org.
Felipe MazaHealth Technology Assessment Unit, Arturo Lopez Perez Foundation, Santiago, RM, Chile.
Diego Carreño-LeitonHealth Technology Assessment Unit, Arturo Lopez Perez Foundation, Santiago, RM, Chile.
Pablo GonzálezRadiotherapy Department, Arturo Lopez Perez Foundation, Santiago, RM, Chile.
Badir ChahuanBreast Surgery Unit, Arturo Lopez Perez Foundation, Santiago, RM, Chile.
Camila QuirlandHealth Technology Assessment Unit, Arturo Lopez Perez Foundation, Santiago, RM, Chile.
Fundación Arturo López Pérez · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdjuvant radiotherapy represents a key component in curative-intent treatment for early-stage breast cancer patients. In recent years, two accelerated partial breast irradiation (APBI) techniques are preferred for this population in our organization: electron-based Intraoperative radiation therapy (IORT) and Linac-based External Beam Radiotherapy, particularly Intensity-modulated radiation therapy (IMRT). Recently published long-term follow-up data evaluating these technologies have motivated a health technology reassessment of IORT compared to IMRT.

methodsWe developed a Markov model to simulate health-state transitions from a cohort of women with early-stage breast cancer, after lumpectomy and adjuvant APBI using either IORT or IMRT techniques. The cost-effectiveness from a private health provider perspective was assessed from a disinvestment point of view, using life-years (LYs) and recurrence-free life-years (RFLYs) as measure of benefits, along with their respective quality adjustments. Expected costs and benefits, and the incremental cost-effectiveness ratio (ICER) were reported. Finally, a sensitivity and scenario analyses were performed to evaluate the cost-effectiveness using lower IORT local recurrence and metastasis rates in IORT patients, and if equipment maintenance costs are removed.

resultsIORT technology was dominated by IMRT in all cases (i.e., fewer benefits with greater costs). Despite small differences were found regarding benefits, especially for LYs, costs were considerably higher for IORT. For sensitivity analyses with lower recurrence and metastasis rates for IORT, and scenario analyses without equipment maintenance costs, IORT was still dominated by IMRT.

conclusionsFor this cohort of patients, IMRT was, at least, non-inferior to IORT in terms of expected benefits, with considerably lower costs. As a result, IORT disinvestment should be considered, favoring the use of IMRT in these patients.

Indexed as

Breast NeoplasmsRadiotherapy, Intensity-ModulatedCost-Benefit AnalysisFemaleHumansIntraoperative CareMastectomy, SegmentalRadiotherapy, AdjuvantAdjuvant radiotherapyBreast cancerCost-effectiveness analysisDisinvestmentIMRTIORT

Identifiers

PMID38570764
PMCPMC10988977
OpenAlexW4393858071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.